Exploring antibody-drug conjugates (ADCs) in lung cancer

Exploring antibody-drug conjugates (ADCs) in lung cancer

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current...Подробнее

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current...

The exciting future of targeted therapies – Exploring new ways to target cancer cellsПодробнее

The exciting future of targeted therapies – Exploring new ways to target cancer cells

WCLC 2024 Highlights - Exploring Latest Advances in Lung Cancer TreatmentПодробнее

WCLC 2024 Highlights - Exploring Latest Advances in Lung Cancer Treatment

Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and ...Подробнее

Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and ...

HERTHENA-Lung02: exploring patritumab deruxtecan in NSCLCПодробнее

HERTHENA-Lung02: exploring patritumab deruxtecan in NSCLC

Exploring Innovations in Oncology: Insights from Dr. Brian Abbott, MD, AllucentПодробнее

Exploring Innovations in Oncology: Insights from Dr. Brian Abbott, MD, Allucent

The LUMINOSITY Trial: Exploring c-Met and SEZ6 Targets in the Future of ADCs for NSCLCПодробнее

The LUMINOSITY Trial: Exploring c-Met and SEZ6 Targets in the Future of ADCs for NSCLC

Advances in Antibody-Drug Conjugates Presentation by Advaith Dinesh at Polygence's SymposiumПодробнее

Advances in Antibody-Drug Conjugates Presentation by Advaith Dinesh at Polygence's Symposium

Advances in Antibody-Drug Conjugates Presentation by Advaith Dinesh at Polygence's SymposiumПодробнее

Advances in Antibody-Drug Conjugates Presentation by Advaith Dinesh at Polygence's Symposium

Exploring available third-line treatment options for R/R DLBCL: CAR-T, bispecifics, ADCs & mAbsПодробнее

Exploring available third-line treatment options for R/R DLBCL: CAR-T, bispecifics, ADCs & mAbs

Novel targeted therapies for NSCLC: Exploring HER2 dysregulationПодробнее

Novel targeted therapies for NSCLC: Exploring HER2 dysregulation

Exploring novel therapeutics in lung cancer: insights from BTOG 2024Подробнее

Exploring novel therapeutics in lung cancer: insights from BTOG 2024

Exploring and Combining Therapy OptionsПодробнее

Exploring and Combining Therapy Options

Revolutionizing Lung Cancer Care: Unveiling ESMO 2023's TakeawaysПодробнее

Revolutionizing Lung Cancer Care: Unveiling ESMO 2023's Takeaways

A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLCПодробнее

A Visual Exploration of New Targeted Therapies for EGFR Exon 20 Insertions in NSCLC

Phase III clinical trials exploring targeted combination therapies for patients with UCПодробнее

Phase III clinical trials exploring targeted combination therapies for patients with UC